Skip to main content
Clinical Trials/ISRCTN10000341
ISRCTN10000341
Completed
未知

Anxiety and depression in Parkinson's Disease

niversity College London0 sites350 target enrollmentDecember 6, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Anxiety and depression in Parkinson's Disease
Sponsor
niversity College London
Enrollment
350
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 6, 2021
End Date
July 1, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
niversity College London

Eligibility Criteria

Inclusion Criteria

  • 1\. Participants must be judged by the investigator to have capacity to understand the nature, design, and procedures of the study and must be able to provide a signed and dated informed consent in accordance with Good Clinical Practice (GCP), International Conference on Harmonization (ICH), and local regulations. All subjects must be willing and able to comply with scheduled visits, required study procedures and laboratory tests.
  • 2\. Willing and able to provide written consent
  • 3\. All participants must have adequate visual and auditory acuity according to investigator’s judgement to complete the neuropsychological testing.
  • 4\. People with PD should have confirmed diagnosis of PD according to Movement Disorder Society Clinical Diagnostic Criteria and must have at least two of the following: resting tremor, bradykinesia, rigidity (must have either resting tremor or bradykinesia); OR either asymmetric resting tremor or asymmetric bradykinesia.
  • 5\. Aged 18 \- 89 years
  • 6\. Can tolerate behavioural and psychological testing
  • 7\. Score of or above 14 on the PAS

Exclusion Criteria

  • General exclusion criteria
  • 1\. Past/present psychotic disorder, bipolar disorder/mania or alcohol/substance use disorder (outside a comorbid psychiatric episode) that would interfere in completing assessments or impair the safety of the participant.
  • 2\. History of medical illness that may impair cognitive function (e.g. serious head injury, endocrine disorder)
  • 3\. Atypical PD syndromes due to either drugs (e.g. metoclopramide, flunarizine, neuroleptics) or metabolic disorders (e.g. Wilson’s disease), encephalitis, or degenerative diseases (e.g. progressive supranuclear palsy).
  • 4\. Previously obtained MRI scan with evidence of clinically significant other neurological disorder (in the opinion of the Investigator).
  • MRI exclusion criteria
  • 5\. MRI contraindications such as a pacemaker, aneurysm clip, cochlear implant, neurostimulator, IUD, shrapnel, metal fragments in the eye, a weight of above 250lbs or claustrophobia.
  • 6\. There are no exclusionary medications for this study.
  • 7\. Females who are pregnant, planning pregnancy, or breastfeeding.

Outcomes

Primary Outcomes

Not specified

Similar Trials